Find Funding Opportunities

Withdrawal NINDS Participation PAR-09-251, quot;Optimization Small Molecule Probes the Nervous System R21)" Notice Number: NOT-NS-12-002 Key Dates Release Date: December 21, 2011   Related Notices PAR-09-251; PAR-12-060   Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice informs potential applicants the National Institute Neurological Disorders Stroke NINDS) no longer accept applications under PAR-09-251, quot;Optimization Small Molecule Probes the Nervous System R21)," beginning the February 16, 2012 receipt date. Researchers seeking support chemical optimization small molecules probes preclinical, vivo proof-of-concept experiments the purposes drug discovery should consider PAR-12-060, quot;Solicitation Validated Hits the Discovery in vivo Chemical Probes R01)." following Institutes continue participate PAR-09-251: National Institute Drug Abuse NIDA) National Institute Aging NIA) National Institute Mental Health NIMH) National Eye Institute NEI) National Institute Alcohol Abuse Alcoholism NIAAA) other aspects PAR-09-251 remain unchanged. Inquiries Please direct inquiries to: Rebecca Farkas, PhD Office Translational Research National Institute Neurological Disorders Stroke 6001 Executive Boulevard Neuroscience Center/Room 2109 Bethesda, MD 20892 Telephone: 301) 496-1779 Fax: 301-402-1501 Email: farkasr@ninds.nih.gov

Withdrawal NINDS Participation PAR-10-001, quot;Drug Discovery Nervous System Disorders R01)" Notice Number: NOT-NS-12-008 Key Dates Release Date: December 21, 2011 Related Notices PAR-10-001; PAR-12-060   Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice informs potential applicants that, effective immediately, National Institute Neurological Disorders Stroke NINDS) no longer accept applications under PAR-10-001, quot;Drug Discovery Nervous System Disorders R01)," beginning the February 5, 2012 receipt date. Researchers seeking support chemical optimization small molecules probes preclinical, vivo proof-of-concept experiments the purposes drug discovery should consider PAR-12-060, quot;Solicitation Validated Hits the Discovery in vivo Chemical Probes R01)." following Institutes continue participate PAR-10-001: National Institute Mental Health NIMH) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Drug Abuse NIDA) other aspects PAR-10-001 remain unchanged. Inquiries Please direct inquiries to: Rebecca Farkas, PhD Office Translational Research National Institute Neurological Disorders Stroke 6001 Executive Boulevard Neuroscience Center/Room 2109 Bethesda, MD 20892 Telephone: 301) 496-1779 Fax: 301-402-1501 Email: farkasr@ninds.nih.gov

Notice Technical Assistance Workshop RFA-NS-12-007, quot;Stroke Prevention/Intervention Research Program SPIRP)" Notice Number: NOT-NS-12-006 Key Dates Release Date: December 19, 2011 Date Workshop: February 3, 2012   Related Notices RFA-NS-12-007   Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke sponsoring technical assistance workshop RFA-NS-12-007, Stroke Prevention/Intervention Research Program SPIRP) U54) Friday, February 3, 2012 1:30 pm 4 pm at: Hilton New Orleans Riverside, Room HEC-A Poydras Street New Orleans, LA nbsp;70130 Phone: 1-504-561-0500 purpose this technical assistance workshop to highlight recent changes NINDS are relevant stroke disparities to facilitate understanding the SPIRP funding opportunity announcement was released December 6, 2011.  Those interested applying this announcement should attend meeting.  Presenters this meeting include representatives the NINDS Office Clinical Research other NINDS staff.  event free charge requires registration.  However, email intent attend Technical Assistance Workshop encouraged planning purposes.  Emails the subject line SPIRP Technical Assistance Workshop” should sent waddysp@mail.nih.gov. Inquiries Please direct inquiries to: Salina Waddy, MD National Institute Neurological Disorders Stroke Telephone: 301-496-9135 waddysp@mail.nih.gov

Request Information: Scientific Regulatory Issues be Explored an Upcoming Pluripotent Stem Cell Workshop involving NIH FDA Notice Number: NOT-NS-12-004 Key Dates Release Date: December 12, 2011 Response Due Date: February 9, 2012 Related Notices NOT-NS-10-016   Issued National Institutes Health NIH) Purpose National Institutes Health NIH) the Food Drug Administration FDA) organizing series workshops will engage broader research community regarding requirements necessary translation pluripotent stem cell-derived products the clinic. purpose this RFI to solicit information pertinent developing second workshop, will focus preclinical safety proof-of-concept evaluation including, among topics: clinical relevance the animal models disease, translation cell dose levels animal human, assessment cell engraftment/survival animals, effect delivery site cell behavior, cell disposition post-administration. Background Human pluripotent stem cells the potential both self-renew differentiate specialized cell populations can used repair, replace, regenerate damaged tissue.  characteristics offer substantial promise development therapeutic products address unmet medical needs.  state stem cell science advancing rapidly research activities this area, including those directed clinical application, expected multiply the next few years.  pluripotent stem cells pose additional challenges therapeutic development beyond those encountered other types somatic cellular products? enable effective translation clinical research increase coordination between research regulatory communities, National Institutes Health the Food Drug Administration planning workshop series engage broader research community regarding prerequisites necessary translation investigational pluripotent stem cell-derived products the clinic. first workshop, held March 21-22, 2011, focused establishment stem cell lines banks, covering safety regulatory issues related how original cell line derivation done the case embryonic stem cells, how cells reprogrammed the case iPS cells Day 1: http://videocast.nih.gov/Summary.asp?File=16558; Day 2: http://videocast.nih.gov/Summary.asp?File=16557). second workshop focus preclinical safety proof concept assessment, including, among topics, clinical relevance the animal models disease, translation cell dose levels animal human, assessment cell engraftment/survival animals, effect delivery site cell behavior, cell disposition post-administration,.  third, final, workshop expected focus clinical trial design, including safety monitoring, immunogenicity, immunosuppressant and immune monitoring. Information Requested NIH seeking information will useful developing second workshop the series. Specifically, NIH seeking comment the following five items: 1.  Describe challenges exist the preclinical evaluation pluripotent stem cell-derived products enable translation the laboratory clinical trials. 2.  Present key questions posed pluripotent stem cell biology should addressed using animal models assess safety potential clinical effectiveness.  3.  Identify any laboratories, research institutions, companies countries have experience translational stem cell research can serve models discussion. 4.  Describe can learned our experience other cell therapies is applicable products derived pluripotent stem cells. 5.  Present questions should addressed the workshop. Note: Responses this RFI voluntary. information provided be analyzed may appear various reports.  Any personal identifiers e.g., names, addresses, email addresses, etc.) be removed responses compiled.  Proprietary, classified, confidential, sensitive information should be included your response.  Responses Responses should submitted via email nindsstemcell@mail.nih.gov, will accepted through February 9, 2012.   Request Information RFI) for planning purposes only is a solicitation applications an obligation the part the United States U.S.) Government provide support any ideas identified response it.  Please note the U.S. Government not pay the preparation any comment submitted for use that comment. Inquiries Please direct inquiries to: Susan Marino, Ph.D., Office the Director National Institute Neurological Disorders Stroke National Institutes Health Phone: 301-594-4470 FAX: 301-496-0296 Email: marinosw@ninds/nih.gov

Notice Termination PAR-11-037, quot;Limited Competition: Fogarty International Research Collaboration - Basic Biomedical FIRCA-BB) Research Award R03)" Notice Number: NOT-TW-12-004 Key Dates Release Date: December 9, 2011 Issued Fogarty International Center FIC) National Cancer Institute NCI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform prospective applicants the Fogarty International Center FIC) terminate Funding Opportunity Announcement FOA) PAR-11-037 effective January 11, 2012. Therefore, NIH not accept applications submitted after January 10, 2012 response the Limited Competition: Fogarty International Research Collaboration - Basic Biomedical FIRCA-BB) Research Award R03) originally the final submission date January 10, 2013. Please note this NOTICE only pertains the Basic Biomedical program not the FIRCA Behavioral Social Sciences program. Inquiries Please direct inquiries to: Xingzhu Liu, M.D., Ph.D. FIRCA-BSS Program Officer Division International Training Research Fogarty International Center FIC) National Institutes Health Building 31, Room B2C39 31 Center Drive, MSC 2220 Bethesda, MD 20892-2220 Telephone: 301-496-1653 Fax: 301-402-0779 Email:   Xingzhu.Liu@nih.gov

Notice Termination PAR-10-278, Limited Competition the Global Research Initiative Program, Basic/Biomedical Sciences R01)" Notice Number: NOT-TW-12-003 Key Dates Release Date: December 8, 2011 Issued Fogarty International Center FIC) National Cancer Institute NCI) National Eye Institute NEI) National Institute Aging NIA) National Institute Biomedical Imaging Bioengineering NIBIB) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Office Dietary Supplements ODS) Purpose purpose this Notice to inform prospective applicants the Fogarty International Center FIC) terminate Funding Opportunity Announcement FOA) PAR-10-278 effective March 9, 2012, both AIDS non-AIDS applications. Therefore, NIH not accept applications submitted after March 9, 2012 response the Limited Competition: Global Research Initiative Program, Basic/Biomedical Sciences R01) originally the final submission date March 8, 2013. Please note this NOTICE only pertains the Basic Biomedical program not the GRIP Behavioral Social Sciences program. Inquiries Please direct inquiries to: Xingzhu Liu, M.D., Ph.D. FIRCA-BSS Program Officer Division International Training Research Fogarty International Center FIC) National Institutes Health Building 31, Room B2C39 31 Center Drive, MSC 2220 Bethesda, MD 20892-2220 Telephone: 301-496-1653 Fax: 301-402-0779 Email:   Xingzhu.Liu@nih.gov

Notice Intent Publish Funding Opportunity Announcement the National NeuroAIDS Tissue Consortium NNTC) U01) Notice Number: NOT-MH-12-010 Key Dates Release Date: December 7, 2011 Issued National Institute Mental Health,(NIMH) National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) intend issue Funding Opportunity Announcement FOA) support applications the National NeuroAIDS Tissue Consortium NNTC) U01). NNTC currently consists four clinical sites, California NeuroAIDS Tissue Network CNTN), Manhattan HIV Brain Bank MHBB), National Neurological AIDS Bank NNAB), the Texas NeuroAIDS Research Center TNRC), a Statistics Data Coordinating Center housed Indiana University.  goals the planned FOA to continue having NNTC serve a resource clinical specimens datasets NeuroAIDS investigators.  Applicants encouraged recruit end-stage HIV-infected subjects based current scientific priorities within NeuroAIDS field. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. FOA, will the NIH Cooperative Agreement U01) award mechanism, expected be published Spring 2012 an expected receipt date Fall 2012.  Details the planned FOA provided below.  Research Initiative Details planned FOA intended encourage applications design scientific agenda the NNTC ensure subject recruitment acquisition specimen database resources are relevant NeuroAIDS investigators.  scientific agenda is focused end-stage HIV-associated central peripheral nervous system diseases encouraged may include, yet not limited to, following topics:  a) define pathogenic mechanisms involved HIV Associated Neurocognitive Disorders HAND) the setting long-term Highly Active Anti-Retroviral Therapy HAART); b) study interactions chronic HIV-1 infection, living HAART long term, aging associated neurodegenerative processes, the impact cardiovascular disease HAND; c) discovery research identify parameters contribute HAND end-stage, chronic HIV-1 infection. APPLICATIONS NOT BEING SOLICITED THIS TIME. Inquiries Interested parties contact: Dianne Rausch, Ph.D. Acting Director, Division AIDS Research National Institute Mental Health 6001 Executive Boulevard, Room 6218, MSC 9616 Rockville, MD 20852-9616 Telephone:  301) 443-7281 Email: drausch@mail.nih.gov

Meeting Introduce Network Excellence Neuroscience Clinical Trials NeuroNEXT) Notice Number: NOT-NS-12-005 Key Dates Release Date: December 6, 2011 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Network Excellence Neuroscience Clinical Trials NeuroNEXT) designed increase efficiency clinical trials, facilitate patient recruitment retention, increase quality neuroscience clinical trials, to enable public-private partnerships. network includes multiple Clinical Sites, Clinical Coordinating Center CCC), one Data Coordinating Center DCC); listing the sites be found the NeuroNEXT website www.ninds.nih.gov/NeuroNEXT). clinical research network provide robust, standardized, accessible infrastructure facilitate rapid development implementation protocols neurological disorders affecting adult and/or pediatric populations. webinar intended give overview the application process NeuroNEXT presentations the NeuroNEXT CCC/DCC NINDS. Time be allotted questions answers. January 6, 2012 3:30 PM - 4:30 PM EST) Teleconference number 1-877-568-4108 Access Code: 415-771-923 Audio PIN: Shown after joining Webinar Weblink:  Reserve Webinar seat at: https://www1.gotomeeting.com/register/770404089 Title: Network Excellence Neuroscience Clinical Trials NeuroNEXT) Date: Friday, January 6, 2012 Time: 3:30 PM - 4:30 PM EST After registering will receive confirmation email containing information joining Webinar. Inquiries Please direct inquiries to: D. Elizabeth McNeil, MD MSc NINDS Telephone: 301-496-9135 mcneilde@ninds.nih.gov www.ninds.nih.gov/NeuroNEXT

Frequently Asked Questions RFA-MH-12-130 - OppNet's Basic Research Decision Making: Cognitive, Affective, Developmental Perspectives R01) Notice Number: NOT-OD-12-019 Key Dates Release Date: December 1, 2011 Issued NIH Basic Behavioral Social Science Opportunity Network OppNet http://oppnet.nih.gov/) its member institutes, centers offices: National Cancer Institute NCI) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) Fogarty International Center FIC) National Center Complementary Alternative Medicine NCCAM) National Center Research Resources NCRR) Office Behavioral Social Sciences Research OBSSR) Office Dietary Supplements ODS) Office Rare Diseases ORD) Office Research Women’s Health ORWH) Purpose OppNet, NIH's Basic Behavioral Social Science Opportunity Network, issued RFA-MH-12-130 - Basic Research Decision Making: Cognitive, Affective, Developmental Perspectives R01) - September 2, 2011.  Previously, OppNet released frequently asked questions FAQs) basic behavioral social science research b-BSSR).  Similarly, OppNet released FAQs answers this OppNet FOA released through member NIMH.  Interested parties find document available the OppNet website: http://oppnet.nih.gov/pdf/FAQsRFA-MH-12-130.pdf.  Potential applicants direct questions the OppNet-affiliated program, grants management, review staff listed the FOA's Section VII. Inquiries Please direct inquiries to: Janine M. Simmons, MD, Ph.D. OppNet RFA Leader Chief, Affect, Social Behavior Social Cognition Program National Institute Mental Health 6001 Executive Boulevard, Room 7179, MSC9637 Bethesda, MD  20892-9637 301-443-1576 janine.simmons@nih.gov William N. Elwood OppNet Facilitator Office Behavioral Social Sciences Research National Institutes Health 31 Center Drive, Suite B1C19, MSC2027 Bethesda, MD  20892-2027 301-402-0116 William.elwood@nih.gov http://oppnet.nih.gov

Notice Total Costs allowed RFA-RM-11-008—H3Africa Collaborative Centers U54) Notice Number: NOT-RM-12-006 Key Dates Release Date:   November 16, 2011 Issued National Institutes Health NIH) National Human Genome Research Institute NHGRI) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) Office AIDS Research OAR) nbsp; Fogarty International Center FIC) Office Strategic Coordination Common Fund) nbsp;  Purpose purpose this Notice to clarify budget requests applications RFA-RM-11-008 should exceed 1 million total costs the collaborative center research, including foreign components, each the five years requested plus 250,000 equipment the first year. Current Language:  Award Budget Applications limited 920,000 direct costs include salaries, supplies, training, equipment, travel, other allowed expenses research grants.  order address H3Africa's goals build infrastructure applicant request to additional 250,000 equipment.  request equipment must very well justified.  subsequent years research plan budget not exceed 920,000 direct costs.  35,000 direct costs/year must also set aside participation the International Extramural Administrative Research Development Program component above) under Implementation H3Africa Objectives section. New Language: Award Budget Applications limited 1 million total costs include salaries, supplies, training, equipment, travel, other allowed expenses research grants.  order address H3Africa's goals build infrastructure applicant request to additional 250,000 equipment the first year.  request equipment must very well justified.  subsequent years research plan budget not exceed 1 million total costs.  all years, 35,000 direct costs/year must set aside participation the International Extramural Administrative Research Development Program component above) under Implementation H3Africa Objectives section. Inquiries Please direct inquiries to: Jane L. Peterson, Ph.D. National Human Genome Research Institute National Institutes Health 5635 Fishers Lane, Suite 4076, MSC 9305 Bethesda, MD 20892-9305 Phone: 301 496 7531 Fax: 301 480 2770 Email: Jane_Peterson@nih.gov H3Africa website: http://H3Africa.org